SCHEMBL14747869

SCHEMBL14747869

CCCC(CC)CCCc1ccc(C)c(OC)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR1A P08908 1/20 0.41
PPARG P37231 1/20 0.41
PPARA Q07869 1/20 0.41
STAT3 P40763 1/20 0.39
SIGMAR1 Q99720 2/20 0.38
CALM1 P0DP23 2/20 0.38
TUBB4A P04350 1/20 0.38
TUBB P07437 1/20 0.38
TUBA3C P0DPH7 1/20 0.38
TUBA1B P68363 1/20 0.38
TUBA4A P68366 1/20 0.38
TUBB4B P68371 1/20 0.38
TUBB3 Q13509 1/20 0.38
TUBB2A Q13885 1/20 0.38
TUBB8 Q3ZCM7 1/20 0.38
TUBA3E Q6PEY2 1/20 0.38
TUBA1A Q71U36 1/20 0.38
TUBA1C Q9BQE3 1/20 0.38
TUBB6 Q9BUF5 1/20 0.38
TUBB2B Q9BVA1 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14747876 0.84 SIGMAR1 (0.43) SIGMAR1CYP3A4
SCHEMBL14747877 0.83 HTR1A (0.56) HTR1APPARGPPARASTAT3TUBB4A
SCHEMBL14747862 0.82 HTR1A (0.40) HTR1APPARGPPARASTAT3SIGMAR1
SCHEMBL12020315 0.81 SKP2 (0.53) HTR1APPARGPPARATUBB4ATUBB
SCHEMBL12961274 0.81 SIGMAR1 (0.43) HTR1APPARGSIGMAR1CYP3A4
SCHEMBL1911890 0.80 SIGMAR1 (0.45) STAT3SIGMAR1CYP3A4
SCHEMBL12856097 0.80 HTR1A (0.44) HTR1ASIGMAR1LTA4HTRPV1CYP1A2
SCHEMBL15760679 0.79 TUBB4A (0.53) PPARGPPARATUBB4ATUBBTUBA3C
SCHEMBL21755693 0.79 HTR1A (0.59) HTR1APPARGPPARASTAT3TUBB4A
Benzene SCHEMBL2920819 0.79 PPARG (0.54) PPARGPPARACYP1A2CYP3A4CYP2C8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2275413-B1 2,4-di(phenylamino)-pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders NOVARTIS AG (CH) 2013-03-06 EP disclosed